Clinical Trial Update: Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety study of an immune response modifier in patients with refractory solid tumors; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Immune Response Modifier

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Neoplasms | Phase 1 | Status: COMPLETED